<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051268</url>
  </required_header>
  <id_info>
    <org_study_id>Typhoid 0319</org_study_id>
    <nct_id>NCT04051268</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)</brief_title>
  <official_title>Immunogenicity and Safety of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults, Children and Infants, Lot to Lot Consistency, Non-inferiority to PQed (Prequalified) TCV (Typhoid Conjugate Vaccine)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed
      typhoid conjugate vaccine and Typhoid Vi polysaccharide vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed
      typhoid conjugate vaccine and to Typhoid Vi polysaccharide vaccine.

      Involved participants aged 6 months old to 60 years old.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">January 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects 6 months - 45 years of age: Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine Subjects 46 - 60 years of age: Randomized, observer blind, lot to lot consistency, superiority to Vi polysaccharide vaccine.
Subjects 6 months - 60 years old: Randomized, observer blind, lot to lot consistency</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Investigational Product and Active Comparator was masking Number of lot was masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>28 days</time_frame>
    <description>Seroconversion following vaccination with one dose of Vi-DT (Bio Farma) in adults, children and infants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe antibody response following vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Comparison of GMT, seroconversion between each lot number of Vi-DT (Bio Farma ) vaccine in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event, solicited or unsolicited</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage with at least one adverse event, solicited or unsolicited, within 30 minutes, 72 hours, 7 days, and 28 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison the safety and immunogenicity</measure>
    <time_frame>28 days</time_frame>
    <description>Comparison of adverse events occuring until 28 days after vaccination between each lot number of Vi-DT (Bio Farma ) vaccine and PQed typhoid conjugate vaccine</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">3071</enrollment>
  <condition>Safety Issues</condition>
  <condition>Immunogenicity</condition>
  <arm_group>
    <arm_group_label>Vi-DT TCV Batch 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml of Vi-DT TCV vaccine batch 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-DT TCV Batch 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml of Vi-DT TCV vaccine batch 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-DT TCV Batch 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml of Vi-DT TCV vaccine batch 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PQed Typhoid Conjugate Vaccine (subjects 6 mo-45 yo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml of PQed TCV Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi Polysaccharide Vaccine (subjects 46-60 years old)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml of Vi Polysaccharide Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi-DT Typhoid Conjugate Vaccine</intervention_name>
    <description>1 dose of Investigational Product</description>
    <arm_group_label>Vi-DT TCV Batch 1</arm_group_label>
    <arm_group_label>Vi-DT TCV Batch 2</arm_group_label>
    <arm_group_label>Vi-DT TCV Batch 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PQed Typhoid Conjugate Vaccine</intervention_name>
    <description>1 dose of Active Comparator</description>
    <arm_group_label>PQed Typhoid Conjugate Vaccine (subjects 6 mo-45 yo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi Polysaccharide Vaccine</intervention_name>
    <description>1 dose of Active Comparator</description>
    <arm_group_label>Vi Polysaccharide Vaccine (subjects 46-60 years old)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy.

          -  Subject/Parents/legal guardian(s) have been informed properly regarding the study and
             signed the informed consent form/and informed assent form.

          -  Subject/parents/legal guardian(s) will commit to comply with the instructions of the
             investigator and the schedule of the trial.

        Exclusion Criteria:

          -  Subject concomitantly enrolled or scheduled to be enrolled in another trial.

          -  Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axilary temperature ³ 37.5°C).

          -  Known history of allergy to any component of the vaccines.

          -  History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular
             injection.

          -  Subject who has received in the previous 4 weeks a treatment likely to alter the
             immune response (intravenous immunoglobulins, blood-derived products, corticosteroid
             therapy and other immunosuppressants)

          -  Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objectives.

          -  Pregnancy &amp; lactation (Adults).

          -  Individuals who have previously received any vaccines against typhoid fever.

          -  Subjects already vaccinated with any vaccine within one month prior and expect to
             receive other vaccines within one month following vaccination except MR (Measles
             Rubella) vaccine.

          -  Individuals who have a previously ascertained typhoid fever by laboratory confirmation
             (blood culture/new rapid test) at any time.

          -  Subject planning to move from the study area before the end of study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernie E Medise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakultas Kedokteran Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novilia S Bachtiar, MD</last_name>
    <phone>+622033755</phone>
    <phone_ext>14101</phone_ext>
    <email>novilia@biofarma.co.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jatinegara Primary Health Care</name>
      <address>
        <city>Jakarta</city>
        <state>Jakart</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernie E Medise, MD</last_name>
      <email>bernie.medise@fk.ui.ac.id</email>
    </contact>
    <investigator>
      <last_name>Bernie E Medise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Typhoid Conjugate Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

